Phase 3 Non Small Cell Clinical Trials
10 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–10 of 10 trials
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled62 locationsNCT07185997
Recruiting
Phase 3
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled229 locationsNCT07222566
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
AstraZeneca744 enrolled302 locationsNCT06417814
Recruiting
Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340
Recruiting
Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Metastatic Non Small Cell Lung Cancer
NovoCure GmbH734 enrolled90 locationsNCT06216301
Recruiting
Phase 3
Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC
Oligometastatic DiseaseMetastatic Non Small Cell Lung Cancer
Tata Memorial Hospital190 enrolled1 locationNCT05278052
Recruiting
Phase 3
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
OligoProgressive Metastatic DiseaseNSCLC Stage IVMetastatic Non Small Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University104 enrolled1 locationNCT06523673
Recruiting
Phase 3
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
Squamous Cell Non Small Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University250 enrolled1 locationNCT05429463
Active
Phase 3
Hypofractionated image guided radiotherapy ("stereotactic") versus conventional radiotherapy for inoperable early stage I non small cell lung cancer (NSCLC).
Stage I non small cell lung cancer
Trans Tasman Radiation Oncology Group (TROG)100 enrolled18 locationsACTRN12610000479000